Apricoxib is an experimental anticancer drug and
nonsteroidal anti-inflammatory drug (NSAID). It is a
COX-2 inhibitor
COX-2 inhibitors are a type of nonsteroidal anti-inflammatory drug (NSAID) that directly targets cyclooxygenase-2, COX-2, an enzyme responsible for inflammation and pain. Targeting selectivity for COX-2 reduces the risk of peptic ulceration and i ...
which is intended to improve standard therapy response in molecularly-defined models of
pancreatic cancer. It was also studied in clinical trials for
non-small-cell lung cancer
Non-small-cell lung cancer (NSCLC) is any type of epithelial lung cancer other than small-cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitive to chemotherapy, compared to s ...
. Development was abandoned in 2015 due to poor clinical trial results.
See also
*
Tilmacoxib
*
Cimicoxib
*
NS-398
NS-398 is a COX-2 inhibitor used in the study of the function of cyclooxygenases.
See also
*Celecoxib
Celecoxib, sold under the brand name Celebrex among others, is a COX-2 inhibitor and nonsteroidal anti-inflammatory drug (NSAID). It is use ...
*
Celecoxib
Celecoxib, sold under the brand name Celebrex among others, is a COX-2 inhibitor and nonsteroidal anti-inflammatory drug (NSAID). It is used to treat the pain and inflammation in osteoarthritis, acute pain in adults, rheumatoid arthritis, ankyl ...
References
COX-2 inhibitors
Sulfonamides
Abandoned drugs
{{musculoskeletal-drug-stub